Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$139M in Q4 2025 → $166M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PO Pyxis Oncology Inc | 21.8% | Added 55% | 15,541,909 | $36.2M |
| Kyverna Therapeutics Inc | 18.5% | Added 6.5% | 4,521,318 | $30.7M |
| TP Teva Pharmaceutical Inds Ltd | 9.0% | New | 379,520 | $15M |
| CT Celldex Therapeutics Inc New | 5.4% | Unchanged | 279,720 | $9.07M |
| Tango Therapeutics Inc | 5.4% | New | 1,852,495 | $9.02M |
| Vir Biotechnology Inc | 5.4% | Trimmed 41% | 803,552 | $8.98M |
| Adarx Pharmaceuticals Inc | 5.4% | New | 450,000 | $8.97M |
| AT Allogene Therapeutics Inc | 5.1% | Unchanged | 5,298,000 | $8.48M |
| BP Bausch Plus Lomb Corp | 4.9% | Trimmed 17% | 475,472 | $8.08M |
| Editas Medicine Inc | 4.8% | Unchanged | 3,127,000 | $8.04M |
| Incyte Corp | 3.7% | Added 18% | 51,080 | $6.2M |
| Taysha Gene Therapies Inc | 3.7% | Trimmed 66% | 248,000 | $6.19M |
| Amgen Inc | 3.7% | Trimmed 28% | 14,512 | $6.12M |
| SR Scholar Rock Hldg Corp | 3.2% | Trimmed 17% | 110,500 | $5.34M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| TP Teva Pharmaceutical Inds Ltd | Exited | −2,402,495 | −$16.4M | — |
| TP Teva Pharmaceutical Inds Ltd | New | +379,520 | +$15M | 9.0% |
| PO Pyxis Oncology Inc | Added | +5,517,000 | +$12.9M | 21.8% |
| Taysha Gene Therapies Inc | Trimmed | −475,185 | −$11.9M | 3.7% |
| UP Ultragenyx Pharmaceutical In | Exited | −289,101 | −$9.65M | — |
| Tango Therapeutics Inc | New | +1,852,495 | +$9.02M | 5.4% |
| Adarx Pharmaceuticals Inc | New | +450,000 | +$8.97M | 5.4% |
| Vir Biotechnology Inc | Trimmed | −550,000 | −$6.15M | 5.4% |
| Sionna Therapeutics Inc | Exited | −136,000 | −$5.98M | — |
| CP Crinetics Pharmaceuticals In | Exited | −126,985 | −$4.75M | — |
Showing the 10 largest of 16 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PO Pyxis Oncology Inc | Added | +5,903,039 | +$17.8M | 14.6% |
| Editas Medicine Inc | New | +3,127,000 | +$10.1M | 4.9% |
| AT Allogene Therapeutics Inc | Added | +3,868,000 | +$8.05M | 5.3% |
| TP Teva Pharmaceutical Inds Ltd | Added | +1,145,000 | +$7.8M | 7.9% |
| CT Celldex Therapeutics Inc New | Added | +109,413 | +$4.07M | 5.0% |
| Tarsus Pharmaceuticals Inc | Exited | −42,680 | −$2.99M | — |
| Vir Biotechnology Inc | Trimmed | −165,000 | −$1.68M | 6.7% |
| Taysha Gene Therapies Inc | Trimmed | −14,365 | −$487K | 11.9% |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Taysha Gene Therapies Inc | Trimmed | −593,351 | −$17.9M | 15.5% |
| SR Scholar Rock Hldg Corp | New | +132,500 | +$6.51M | 4.5% |
| Sionna Therapeutics Inc | New | +136,000 | +$5.45M | 3.8% |
| Vir Biotechnology Inc | Added | +588,235 | +$5.27M | 9.5% |
| CP Crinetics Pharmaceuticals In | Trimmed | −97,150 | −$3.53M | 3.2% |
| AT Allogene Therapeutics Inc | New | +1,430,000 | +$3.49M | 2.4% |
| TP Teva Pharmaceutical Inds Ltd | Added | +487,945 | +$2.18M | 3.9% |
| Tarsus Pharmaceuticals Inc | Trimmed | −24,000 | −$1.68M | 2.1% |
| Kyverna Therapeutics Inc | Trimmed | −147,000 | −$1.27M | 25.5% |
| Amgen Inc | Trimmed | −3,000 | −$1.06M | 5.0% |
Showing the 10 largest of 13 changes.
Loading...